FDA
approval
· 2018-10-11
FDA Approved: EXONDYS 51 — Supplemental Application (Sarepta Therapeutics, Inc.)
Summary
The FDA approved Sarepta Therapeutics' supplemental application for Exondys 51 (eteplirsen) for Duchenne muscular dystrophy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for EXONDYS 51 (ETEPLIRSEN)